Selecting Between Receptor Pathway Inhibitors for mHSPC

EP: 1.An Overview of the ARANOTE Trial

EP: 2.Comparing Trials Studying Treatment Intensification In mHSPC

EP: 3.Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

EP: 4.Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

EP: 5.Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

EP: 6.Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

EP: 7.Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

EP: 8.Using Ultrasensitive PSA Assays in Routine Practice

EP: 9.The Use of Ultra-Low PSA in Specific Patient Profiles

Now Viewing

EP: 10.Selecting Between Receptor Pathway Inhibitors for mHSPC

Therapeutic Decision-Making in Advanced Prostate Cancer

Key Themes:

• Approach to selecting among multiple androgen receptor pathway inhibitors
• Individualization of therapy based on patient factors
• Consideration of drug-specific characteristics

Expert Insights:

• Dr Shore provided guidance on approaching treatment decisions with multiple agents now available (enzalutamide, apalutamide, abiraterone, and darolutamide).
• He emphasized the importance of individualizing therapy based on comorbidities, potential drug-drug interactions, convenience factors, and patient preferences.

The discussion noted darolutamide's lower central nervous system penetration and potentially improved tolerability in certain populations, while acknowledging that all these agents represent effective treatment options.